<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764359</url>
  </required_header>
  <id_info>
    <org_study_id>15-120</org_study_id>
    <nct_id>NCT02764359</nct_id>
  </id_info>
  <brief_title>Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens</brief_title>
  <official_title>Single-Center Prospective Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity alters the movement through the body of several antibiotics, including vancomycin.
      Based on literature to date, total body weight should be used to determine dosages and
      shorter dosing intervals may be needed. However, hospitals have different approaches to
      managing vancomycin in this patient population. The most common example is not exceeding a
      dose of 2,000mg of vancomycin at one time in these patients. However, some institutions
      including the Charleston Area Medical Center do not have a set maximum one time dose. To
      date, a study has not been done comparing two different dosing regimens in obese patients to
      determine if having a maximum dose cap is beneficial.

      This research study is attempting to add to the limited existing body of literature regarding
      vancomycin dosing in obese patients. The investigators hypothesize that optimizing the
      initial or loading vancomycin dose that obese patients receive will decrease the time to
      target concentrations. For this study, obese adult patients will be randomized to receive
      either 1) a loading dose of 20 mg/kg with a maximum dose up to 2,000mg OR 2) a loading dose
      of 20 mg/kg with a maximum dose of up to 4,000mg. The study's primary aim is to determine
      differences in the time needed to achieve target vancomycin concentrations and the occurrence
      of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to attain therapeutic vancomycin concentrations</measure>
    <time_frame>&lt; 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported adverse events</measure>
    <time_frame>48 hours post initial vancomycin dose</time_frame>
    <description>Red Man's syndrome: pruritus and erythematous rash involving the face, neck, and upper torso.
Nephrotoxicity: increase in serum creatinine (SCr) by 0.5 mg/dL or 50% from baseline on two consecutive measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the pharmacokinetic parameter of elimination rate constant (ke) following the loading vancomycin dose</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the pharmacokinetic parameter of volume of distribution (Vd) following the loading vancomycin dose</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Infection</condition>
  <condition>Sepsis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>IV Vancomycin loading dose- higher</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Vancomycin loading dose- lower</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV vancomycin</intervention_name>
    <description>IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.</description>
    <arm_group_label>IV Vancomycin loading dose- higher</arm_group_label>
    <arm_group_label>IV Vancomycin loading dose- lower</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age who present to the Charleston Area Medical Center-Memorial
             Hospital Emergency Department

          -  Weight &gt;100kg

          -  Infection requiring intravenous vancomycin and admission to Charleston Area Medical
             Center-Memorial Hospital

        Exclusion Criteria:

          -  Any patient &lt;18 years of age

          -  Patients on dialysis or with unstable renal function (a change of &gt;0.5 mg/dL in SCr
             concentration in patients with a SCr of &lt;2 mg/dL or a 20% change in SCr in patients
             with a SCr of ≥2 mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Payne, MD</last_name>
    <phone>304-388-6004</phone>
    <email>Murnau@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Crawford, DO</last_name>
    <phone>304-388-6004</phone>
    <email>acrawford@osteo.wvsom.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CAMC Health Systems</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Payne, MD</last_name>
      <phone>304-388-6004</phone>
      <email>Murnau@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Adam Crawford, DO</last_name>
      <phone>304-388-6004</phone>
      <email>acrawford@osteo.wvsom.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Payne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Crawford, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>William Payne</investigator_full_name>
    <investigator_title>Emergency Medicine Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

